Angiocrine growth factors

Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial Data during the Annual Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Monday, February 13, 2023
Regenerative Medicine Advanced Therapy, HDT, AB-205, Regenerative medicine, Hospital, Lymphoma, Safety, California Institute for Regenerative Medicine, CIRM, Efficacy, Center for International Blood and Marrow Transplant Research, Food, SAN, SOC, Society, Transplant, US Foods, MD, Pharmaceutical industry, Angiocrine growth factors

AB-205 is an intravenous investigational engineered cell therapy product being developed for multiple indications.

Key Points: 
  • AB-205 is an intravenous investigational engineered cell therapy product being developed for multiple indications.
  • "Our investigators and Angiocrine are honored to be selected by ASTCT & CIBMTR to present at its annual meeting this February," commented Paul Finnegan, MD, Angiocrine CEO.
  • "We look forward to Dr. Michael Scordo's presentation on the trial design of our AB-205 Phase 3 multi-center study (E-CELERATE)."
  • Additionally, the California Institute for Regenerative Medicine (CIRM) has approved investing $15M in this Phase 3 registration study.

Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology (ASH)

Retrieved on: 
Friday, December 9, 2022
ClinicalTrials.gov, Food, Collateral damage, MD, Endothelium, Hospital, Society, Patient, National Institutes of Health, AB-205, US Food Sovereignty Alliance, Lymphoma, Safety, HDT, Tissue, Regenerative medicine, Infection, SAN, ASH, Pharmaceutical industry, Angiocrine growth factors

"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO.

Key Points: 
  • "Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO.
  • "We look forward to Dr. Michael Scordo's presentation on the trial design of our AB-205 Phase 3 multi-center study (E-CELERATE)."
  • Angiocrine Bioscience, Inc. is a clinical-stage biopharmaceutical company developing Advanced Reparative Medicines consisting of engineered human endothelial cells (E-CEL cells).
  • Angiocrine utilizes its proprietary E-CEL Platform to create multiple versions of E-CEL cells to repair damaged tissues and organs and to treat serious medical conditions.